There were 765 press releases posted in the last 24 hours and 392,041 in the last 365 days.

Radius Health to Present at the 36th Annual Canaccord Genuity Growth Conference

WALTHAM, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 36th Annual Canaccord Genuity Growth Conference on August 10, 2016 at 4:00 pm EDT at the InterContinental Hotel in Boston, MA.

The Company's presentation will be webcast live on the Company's website at, and a replay of the presentation will be available on the Company's website following the presentation. The Company will post a copy of the presentation materials on its website,, prior to the start of the presentation.

About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe, and a New Drug Application (NDA) has been accepted for filing by the FDA.  The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.

Investor Relations Contact:
Barbara Ryan
Phone: 203-274-2825

Media Contact:
Lori Gorski
Phone: 617-551-4096